[Results of immunosuppressive therapy in 78 patients with rheumatoid polyarthritis, treated for at least 4 years]. 1975

J C Renier, and C Bregeon, and C Bonnette

The authors report clinical, laboratory, and radiological results obtained by immunodepresant treatment of 78 patients suffering from rheumatoid polyarthritis, over a period of more than 4 years. In 27 of the patients the treatment had been followed for 4 to 8 years. Clinically the results were excellent in 36 cases, reasonably good in 23 cases; in 19 cases therapy was unsuccessful or had to to be stopped. There was a reduction in the sedimentation rate in cases with good results and in half the cases there was a reduction in the titre of the Waaler-Rose reaction. Studies on the evolution of radiological signs in 34 patients showed definite deterioration in only 2 cases out of 19 subjects having very good clinical results and definite deterioration in 7 of 15 subjects with less good clinical results or failure. Thus the immunodepressant treatment appeared capable of stopping or slowing down the osteoarticular destruction. The cessation of treatment in 28 patients was followed by a relapse in 14 patients (7 within 6 months, and 7 within 6 months to 2 years). In 14 patients there was no relapse and in 8 of these the improvement has lasted for more than 3 years. With the doses used, there were few short-term complications of treatment. Haematological tolerance appeared to vary according to the patient ; for prolonged treatment the dose should be adapted to the individual.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007239 Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases. Infection,Infection and Infestation,Infections and Infestations,Infestation and Infection,Infestations and Infections
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011859 Radiography Examination of any part of the body for diagnostic purposes by means of X-RAYS or GAMMA RAYS, recording the image on a sensitized surface (such as photographic film). Radiology, Diagnostic X-Ray,Roentgenography,X-Ray, Diagnostic,Diagnostic X-Ray,Diagnostic X-Ray Radiology,X-Ray Radiology, Diagnostic,Diagnostic X Ray,Diagnostic X Ray Radiology,Diagnostic X-Rays,Radiology, Diagnostic X Ray,X Ray Radiology, Diagnostic,X Ray, Diagnostic,X-Rays, Diagnostic
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001799 Blood Sedimentation Measurement of rate of settling of ERYTHROCYTES in blood. Erythrocyte Sedimentation,Erythrocyte Sedimentation Rate,Erythrocyte Sedimentation Rates,Rate, Erythrocyte Sedimentation,Rates, Erythrocyte Sedimentation,Sedimentation Rate, Erythrocyte,Sedimentation Rates, Erythrocyte,Sedimentation, Blood,Sedimentation, Erythrocyte
D002699 Chlorambucil A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed) 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid,Amboclorin,CB-1348,Chloraminophene,Chlorbutin,Leukeran,Lympholysin,N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid,NSC-3088,CB 1348,CB1348,NSC 3088,NSC3088

Related Publications

J C Renier, and C Bregeon, and C Bonnette
January 1993, Zeitschrift fur Rheumatologie,
J C Renier, and C Bregeon, and C Bonnette
January 1969, Studii si cercetari de medicina interna,
J C Renier, and C Bregeon, and C Bonnette
January 1969, Zeitschrift fur Rheumaforschung,
J C Renier, and C Bregeon, and C Bonnette
April 1990, Revue du rhumatisme et des maladies osteo-articulaires,
J C Renier, and C Bregeon, and C Bonnette
March 1968, La Revue lyonnaise de medecine,
J C Renier, and C Bregeon, and C Bonnette
January 1972, Therapeutique (La Semaine des hopitaux),
J C Renier, and C Bregeon, and C Bonnette
January 1977, Revista espanola de reumatismo y enfermedades osteoarticulares,
J C Renier, and C Bregeon, and C Bonnette
December 1971, Revue du rhumatisme et des maladies osteo-articulaires,
J C Renier, and C Bregeon, and C Bonnette
February 1993, Revue du rhumatisme (Ed. francaise : 1993),
J C Renier, and C Bregeon, and C Bonnette
April 1972, Medizinische Monatsschrift,
Copied contents to your clipboard!